TV-90105
Total Payments
$1.2M
Transactions
17
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $1.2M | 17 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.2M | 17 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| TV90105-PK-10117 | Teva Pharmaceuticals USA, Inc. | $576,464 | 0 |
| TV90105-PK-10081 | Teva Pharmaceuticals USA, Inc. | $381,147 | 0 |
| TV90105-BA-10080 | Teva Pharmaceuticals USA, Inc. | $257,345 | 0 |
Top Doctors Receiving Payments for TV-90105
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Salt Lake City, UT | $1.2M | 17 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $1.2M
- Total Doctors 0
- Transactions 17
About TV-90105
TV-90105 is a drug associated with $1.2M in payments to 0 healthcare providers, recorded across 17 transactions in the CMS Open Payments database. The primary manufacturer is Teva Pharmaceuticals USA, Inc..
Payment data is available from 2017 to 2017. In 2017, $1.2M was paid across 17 transactions to 0 doctors.
The most common payment nature for TV-90105 is "Unspecified" ($1.2M, 100.0% of total).
TV-90105 is associated with 3 research studies, including "TV90105-PK-10117" ($576,464).